The FDA has approved a subcutaneous formulation of lecanemab (Leqembi Iqlik, Eisai/Biogen) for maintenance dosing in patients with Alzheimer’s disease (AD) with mild cognitive impairment (MCI) or mild ...

The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase. Leqembi Iqlik is a subcutaneous ...

A new analysis from the PALOMA-2 study shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in ...

Leqembi Iqlik's subcutaneous injection for Alzheimer's disease received FDA approval, based on Phase III trial data showing comparable efficacy to IV dosing. The subcutaneous formulation demonstrated ...

The breakout signals the end of the recent pullback from record highs above $124,000 and the resumption of the broader rally. Using the measured move technique, which adds the distance between the ...

Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...

LEHI, Utah--(BUSINESS WIRE)--Pattern Group Inc. (“Pattern”), a leader in accelerating brands on global ecommerce marketplaces leveraging proprietary technology and AI, today announced that it has ...

FDA Approves Subcutaneous Leqembi for Treatment of Early Alzheimer Disease By Stephanie Brown HealthDay ReporterTUESDAY, Sept. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

(Reuters) - Pattern is seeking a valuation of up to $2.64 billion in its initial public offering in the United States, the e-commerce firm said on Wednesday, in a further sign of resurgent new ...

Anyone who’s drinking hot pumpkin spice lattes in a chunky sweater may need to rein it in for a little while. The crisp weather many in the United States enjoyed over the last week or two was just a ...

A new campaign from Aflac aims to be more than just a one-off awareness push. Instead, the supplemental health insurance company is hoping it’ll become a full-blown “pop culture phenomenon,” according ...